Live Analyst Rating Changes 21390 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Susannah Ludwig
BERN

Susannah Ludwig

Bernstein
Wall Street Analyst
★★★☆☆
#1084
on 13Foresight · ranked by our own returns
67%
Success Rate
+3.8%
Average Return
14 of 21 calls profitable · -6.6% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 67% of Susannah Ludwig's ratings turned a profit when each position was held for 1 year — averaging +3.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 19 Hold 6 Sell
Susannah's Stock Coverage 17 ratings · 2026-08-09
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
DE:AFX
Carl Zeiss Meditec
 Aug 06, 2026 HOLD Hold
+57.5% avg upside
13 analysts
$26.10
12.73% Downside
 · ·
FMS
Fresenius Medical Care
 Aug 06, 2026 HOLD Hold
+68.5% avg upside
15 analysts
$25.80
6.35% Upside
 · ·
DE:FME
Fresenius Medical Care AG & Co. KGaA
 Aug 04, 2026 HOLD Hold
+19.7% avg upside
23 analysts
$44.65
6.12% Upside
 +1.4% ·
DE:SHL
Siemens Healthineers AG
 Aug 04, 2026 BUY Buy
+24.7% avg upside
24 analysts
$44.50
12.65% Upside
 -0.4% ·
NL:PHIA
Koninklijke Philips N.V.
 Jul 28, 2026 HOLD Buy
+31.6% avg upside
21 analysts
$25.40
9.81% Upside
 +0.8% ·
WILLF
Demant
 Jul 17, 2026 HOLD Buy
-4.1% avg upside
19 analysts
$42.54
1.81% Downside
 +4.3% ·
CH:SOON
Sonova Holding AG
 Mar 25, 2026 BUY Hold
-5.4% avg upside
18 analysts
$256.00
8.60% Upside
 +37.7% ·
GB:0K9P
GN Store Nord
 Mar 25, 2026 SELL Hold
+143.2% avg upside
13 analysts
$84.00
14.88% Downside
 · ·
FR:DIM
Sartorius Stedim Biotech
 Mar 16, 2026 BUY Strong Buy
+40.6% avg upside
11 analysts
$245.00
37.62% Upside
 +0.4% ·
DE:GXI
Gerresheimer
 Mar 16, 2026 SELL Buy
+135.9% avg upside
16 analysts
$18.90
28.13% Downside
 -36.8% ·
DE:SRT3
Sartorius
 Mar 16, 2026 BUY Buy
+18.0% avg upside
18 analysts
$284.00
22.36% Upside
 +2.1% ·
GB:0QBO
Coloplast A/S
 Jan 28, 2026 HOLD Buy
+66.7% avg upside
17 analysts
$555.00
26.87% Upside
 · ·
GB:CTEC
ConvaTec
 Jan 28, 2026 BUY Strong Buy
+28.0% avg upside
18 analysts
$295.00
27.03% Upside
 -1.0% ·
CH:ALC
Alcon
 Aug 21, 2025 BUY Buy
+24.1% avg upside
35 analysts
$84.50
47.46% Upside
 -13.8% ·
IT:AMP
Amplifon S.p.A.
 Jul 31, 2025 HOLD Buy
+100.4% avg upside
13 analysts
$15.95
33.40% Upside
 -22.2% ·
CH:STMN
Straumann Holding AG
 Jun 27, 2025 BUY Buy
+23.2% avg upside
15 analysts
$148.00
43.83% Upside
 +3.9% ·
AU:COH
Cochlear
May 12, 2023 HOLD Hold
+41.4% avg upside
15 analysts
$240.00
92.27% Upside
 +32.4% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Susannah Ludwig — Frequently Asked Questions
How accurate are Susannah Ludwig's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Susannah's ratings were profitable over a one-year hold, with an average return of +3.8% per rating, or -6.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Susannah ranked on 13Foresight?
Susannah Ludwig is currently ranked #1084 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Susannah cover?
Susannah most recently has ratings on DE:AFX, FMS, DE:FME, DE:SHL, NL:PHIA, WILLF, CH:SOON, GB:0K9P, FR:DIM, DE:GXI, DE:SRT3, GB:0QBO and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.